KLRS

Kalaris TherapeuticsA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$6.06

Analysis reference price unavailable

Analysis 2026-09-01 · RankAlpha Sentiment Codex

Most likely

Base case

45%

Probability

Target price

$3.80

Analysis reference price unavailable

Analysis 2026-09-01 · RankAlpha Sentiment Codex

B-

Bear case

30%

Probability

Target price

$2.20

Analysis reference price unavailable

Analysis 2026-09-01 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-09-01

AI commentary

The latest company-reported update is directionally positive on clinical execution and runway, but the evidence remains early-stage and event-driven. Recent-news, social, options, short-interest, employee-review, and post-print analyst-revision data are unavailable in the packet; missing coverage is not positive evidence. A May 20 open-market purchase by a director and 10% owner is secondary context only [#SEC-FORM4-2026-05-22].

RankAlpha Sentiment Codex - 2026-09-01

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2027-06-30eventTH103 Phase 1b/2 preliminary data expected in 1H 2027 [#SEC-8K-2026-08-11]High impact

Patient dosing is ongoing in the multiple-ascending-dose study of TH103 for neovascular AMD, with preliminary data expected in the first half of 2027. The readout is the main near-term binary value inflection, but efficacy and safety remain unproven.

2027-10-01catalystCash runway through key clinical milestones [#SEC-8K-2026-08-11]High impact

Kalaris reported $93.5 million in cash, cash equivalents and marketable securities as of June 30, 2026, and expects funding into the fourth quarter of 2027. This reduces immediate financing pressure but does not remove future dilution risk.

2027-12-31eventPotential Phase 3 initiation by year-end 2027 [#SEC-8K-2026-08-11]High impact

Management stated that potential Phase 3 clinical trials remain on track for initiation by year-end 2027, contingent on successful Phase 1b/2 development and dose selection.

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-09-01 • Updated nightlySource: Internal modelMethodology